The Lupus Research Alliance applauds the approval by the U.S. Food and Drug Administration of Gazyva® (obinutuzumab) from ...
Phenotyping patients can help to identify potential heart failure with preserved ejection fraction (HFpEF) as well as improve patient outcomes.
The FDA has approved Genentech’s Gazyva (obinutuzumab) for the treatment of lupus nephritis in adults, according to a news release published today. Gazyva is the first and only anti-CD20 monoclonal ...
The drug is the only medicine of its kind proven to help patients with lupus nephritis regain full kidney response, the ...
11hon MSN
Nearly 90% of adults are at risk for this condition, but most have never heard of it, survey finds
About 9 in 10 adults in the United States have not heard of cardiovascular-kidney-metabolic syndrome despite nearly 90% of ...
"The pervasive presence of phthalates results in nearly unavoidable exposure in the general population, with CKD patients likely experiencing even higher levels due to their medical treatment ...
POXEL SA (Euronext: POXEL - FR0012432516), informs that a first document in response to the questions received from the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback